Overview

CISPLATIN + AZD-1775 In Breast Cancer

Status:
Completed

Trial end date:
2020-11-30

Target enrollment:

Participant gender:

Summary

This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions involved in this study are: - Cisplatin - AZD1775

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

AstraZeneca

Treatments:

Adavosertib
Cisplatin